🚀 VC round data is live in beta, check it out!
Siegfried Valuation Multiples
Discover revenue and EBITDA valuation multiples for Siegfried and similar public comparables like Laboratorios Rovi, Genscript Biotech, Avantor, Brightgene Bio-medical and more.
Siegfried Overview
About Siegfried
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
Founded
1873
HQ
Employees
3.7K
Website
Financials (LTM)
EV
$5B
Siegfried Financials
Siegfried reported last 12-month revenue of $2B and EBITDA of $410M.
In the same LTM period, Siegfried generated $467M in gross profit, $410M in EBITDA, and $221M in net income.
Revenue (LTM)
Siegfried P&L
In the most recent fiscal year, Siegfried reported revenue of $2B and EBITDA of $404M.
Siegfried expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $467M | XXX | $452M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA | $410M | XXX | $404M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $221M | XXX | $218M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Siegfried Stock Performance
Siegfried has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Siegfried's stock price is $107.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 2.1% | XXX | XXX | XXX | $4.97 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSiegfried Valuation Multiples
Siegfried trades at 2.6x EV/Revenue multiple, and 11.1x EV/EBITDA.
EV / Revenue (LTM)
Siegfried Financial Valuation Multiples
As of April 18, 2026, Siegfried has market cap of $5B and EV of $5B.
Equity research analysts estimate Siegfried's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Siegfried has a P/E ratio of 21.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 16.1x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 21.6x | XXX | XXX | XXX |
| EV/FCF | 52.4x | XXX | 67.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Siegfried Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Siegfried Margins & Growth Rates
Siegfried's revenue in the last 12 month grew by 6%.
Siegfried's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.0M for the same period.
Siegfried's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Siegfried's rule of X is 38% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Siegfried Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Siegfried Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Siegfried | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Rovi | XXX | XXX | XXX | XXX | XXX | XXX |
| Genscript Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantor | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Asymchem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Siegfried M&A Activity
Siegfried acquired XXX companies to date.
Last acquisition by Siegfried was on XXXXXXXX, XXXXX. Siegfried acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Siegfried
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSiegfried Investment Activity
Siegfried invested in XXX companies to date.
Siegfried made its latest investment on XXXXXXXX, XXXXX. Siegfried invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Siegfried
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Siegfried
| When was Siegfried founded? | Siegfried was founded in 1873. |
| Where is Siegfried headquartered? | Siegfried is headquartered in Switzerland. |
| How many employees does Siegfried have? | As of today, Siegfried has over 3K employees. |
| Is Siegfried publicly listed? | Yes, Siegfried is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Siegfried? | Siegfried trades under SFZN ticker. |
| When did Siegfried go public? | Siegfried went public in 1973. |
| Who are competitors of Siegfried? | Siegfried main competitors are Laboratorios Rovi, Genscript Biotech, Avantor, Brightgene Bio-medical. |
| What is the current market cap of Siegfried? | Siegfried's current market cap is $5B. |
| What is the current revenue of Siegfried? | Siegfried's last 12 months revenue is $2B. |
| What is the current revenue growth of Siegfried? | Siegfried revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Siegfried? | Current revenue multiple of Siegfried is 2.6x. |
| Is Siegfried profitable? | Yes, Siegfried is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Siegfried? | Siegfried's last 12 months EBITDA is $410M. |
| What is Siegfried's EBITDA margin? | Siegfried's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Siegfried? | Current EBITDA multiple of Siegfried is 11.1x. |
| What is the current FCF of Siegfried? | Siegfried's last 12 months FCF is $87M. |
| What is Siegfried's FCF margin? | Siegfried's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Siegfried? | Current FCF multiple of Siegfried is 52.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.